Andreas Wollenberg

List of Publications by Year
in descending order

208 papers	18,527 citations	14655 66 h-index	13379 130 g-index
251 all docs	251 docs citations	251 times ranked	9973 citing authors

#	Article	IF	Citations
1	Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. Journal of Dermatological Treatment, 2022, 33, 1521-1530.	2.2	25
2	Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. Journal of Dermatological Treatment, 2022, 33, 266-277.	2.2	17
3	Conjunctivitis in adult patients with moderateâ€toâ€severe atopic dermatitis: results from five tralokinumab clinical trials. British Journal of Dermatology, 2022, 186, 453-465.	1.5	43
4	Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderateâ€toâ€severe atopic dermatitis*. British Journal of Dermatology, 2022, 186, 285-294.	1.5	13
5	Atopic dermatitis: disease characteristics and comorbidities in smoking and nonâ€smoking patients from the TREATgermany registry. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 413-421.	2.4	8
6	Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
7	Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitisâ€”A pooled analysis of trial data. Pediatric Dermatology, 2022, 39, 187-196.	0.9	23
8	Sensitive skin: A relevant syndrome, be aware. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 3-5.	2.4	1
9	Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta Dermato-Venereologica, 2022, 102, adv00726.	1.3	4
10	Perception of the coronavirus pandemic by patients with atopic dermatitis â€“ Results from the TREATgermany registry. JDDG - Journal of the German Society of Dermatology, 2022, 20, 45-57.	0.8	3
11	Determinants of costs and benefits in atopic dermatitis routine care in Germany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1450-1455.	2.4	3
12	An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderateâ€toâ€severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1486-1496.	2.4	10
13	Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1432-1449.	2.4	28
14	Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial. Journal of the American Academy of Dermatology, 2021, 84, 495-497.	1.2	6
15	Tralokinumab for moderateâ€toâ€severe atopic dermatitis: results from two 52â€week, randomized, doubleâ€blind, multicentre, placeboâ€controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British Journal of Dermatology, 2021, 184, 437-449.	1.5	289
16	2020 European guideline on the management of genital molluscum contagiosum. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 17-26.	2.4	29
17	Update â€œSystemic treatment of atopic dermatitisâ€•of the S2kâ€guideline on atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 151-168.	0.8	30
18	Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD. Dermatology and Therapy, 2021, 11, 221-233.	3.0	12

#	Article	IF	Citations
19	Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organization Journal, 2021, 14, 100519.	3.5	48
20	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVIDâ€19 (SARSâ€CoVâ€2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e308-e311.	2.4	27
21	â€œFace mask dermatitisâ€• due to compulsory facial masks during the SARS-CoV-2 pandemic: data from 550 health care and non-health care workers in Germany. European Journal of Dermatology, 2021, 31, 199-204.	0.6	17
22	Inborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1501-1507.	3.8	13
23	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASIÂâ‰¥Â16) analysis of randomized phase 2B study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1562-1568.	2.4	33
24	Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib. Dermatitis, 2021, 32, S53-S61.	1.6	15
25	Risk of severe allergic reactions to COVIDâ€19 vaccines among patients with allergic skin diseases â€“ practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e362-e365.	2.4	24
26	Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2021, 126, 576-583.e4.	1.0	16
27	Costâ€ofâ€illness of atopic dermatitis in Germany: data from dermatology routine care. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1346-1356.	2.4	19
28	Increased prevalence of irritant hand eczema in health care workers in a dermatological clinic due to increased hygiene measures during the SARS-CoV-2 pandemic. European Journal of Dermatology, 2021, 31, 392-395.	0.6	14
29	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderateâ€toâ€severe atopic dermatitis from the BREEZEâ€AD7 Phase 3 randomized trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1543-1552.	2.4	41
30	Rat bite fever, a diagnostic challenge: case report and review of 29 cases. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1283-1287.	0.8	6
31	Position statement on the role of nurses in therapeutic patient education in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2143-2148.	2.4	5
32	Tralokinumab in atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1435-1442.	0.8	6
33	Laboratory Safety of Dupilumab in Patients Aged 6â€“11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatric Drugs, 2021, 23, 515-527.	3.1	15
34	Pharmacist recommendations regarding topical steroid use may contradict the standard of care in atopic dermatitis: An international, cross-sectional study. JAAD International, 2021, 4, 13-14.	2.2	0
35	Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials. SKIN the Journal of Cutaneous Medicine, 2021, 5, s11.	0.3	5
36	Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council. Dermatitis, 2021, 32, 319-326.	1.6	9

#	Article	IF	Citations
37	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6ÂYears of Age and Older. Dermatology and Therapy, 2021, 11, 1643-1656.	3.0	1
38	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment, 2020, 31, 606-614.	2.2	72
39	Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. Journal of Allergy and Clinical Immunology, 2020, 145, 173-182.	2.9	183
40	Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). British Journal of Dermatology, 2020, 182, 1120-1135.	1.5	92
41	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. British Journal of Dermatology, 2020, 182, 1331-1342.	1.5	102
42	Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1263-1272.	2.4	41
43	Efficacy of a skin care cream with TRPV1 inhibitor 4â€tâ€butylcyclohexanol in the topical therapy of perioral dermatitis. Journal of Cosmetic Dermatology, 2020, 19, 1409-1414.	1.6	7
44	Recurrent eczema herpeticum â€“ a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1074-1079.	2.4	32
45	Quality of care in atopic dermatitis â€“ a position statement by the European Task Force on Atopic Dermatitis (<scp>ETFAD</scp>). Journal of the European Academy of Dermatology and Venereology, 2020, 34, e136-e138.	2.4	8
46	Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 255-266.	13.7	273
47	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2717-2744.	2.4	220
48	Dupilumab for the treatment of adolescents with atopic dermatitis. Expert Review of Clinical Immunology, 2020, 16, 641-650.	3.0	12
49	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11Âyears old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 2020, 83, 1282-1293.	1.2	214
50	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e839-e842.	2.4	22
51	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARSâ€Covâ€2) infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e241-e242.	2.4	99
52	Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <scp>TREAT</scp> germany. British Journal of Dermatology, 2020, 183, 382-384.	1.5	37
53	Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. New England Journal of Medicine, 2020, 382, 706-716.	27.0	189
54	Baricitinib in patients with moderateâ€toâ€severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials. British Journal of Dermatology, 2020, 183, 242-255.	1.5	277

#	Article	IF	Citations
55	Linear patterns of the skin and their dermatoses. JDDG - Journal of the German Society of Dermatology, 2020, 18, 341-364.	0.8	4
56	Evaluation of hand hygiene and onset of hand eczema after the outbreak of SARS-CoV-2 in Munich. European Journal of Dermatology, 2020, 30, 668-673.	0.6	18
57	The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Experimental Dermatology, 2019, 28, 3-10.	2.9	51
58	Evaluation of antimicrobial textiles for atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 384-390.	2.4	23
59	Food-Related Contact Dermatitis, Contact Urticaria, and Atopy Patch Test with Food. Clinical Reviews in Allergy and Immunology, 2019, 56, 19-31.	6.5	39
60	Treatment of atopic dermatitis with tralokinumab, an antiâ€“IL-13 mAb. Journal of Allergy and Clinical Immunology, 2019, 143, 135-141.	2.9	294
61	Management der Dupilumabâ€assoziierten Konjunktivitis beim atopischen Ekzem. JDDG - Journal of the German Society of Dermatology, 2019, 17, 488-492.	0.8	6
62	A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease â€“ strategies for optimizing treatment outcome. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2253-2263.	2.4	54
63	Defining and measuring â€˜eczema controlâ€™: an international qualitative study to explore the views of those living with and treating atopic eczema. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1124-1132.	2.4	16
64	Pathomechanism of dupilumabâ€associated inflammatory eye symptoms. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e435-e436.	2.4	18
65	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1644-1659.	2.4	85
66	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy â€“ international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1224-1231.	2.4	50
67	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 753-754.	3.8	2
68	Management of dupilumabâ€associated conjunctivitis in atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2019, 17, 488-491.	0.8	27
69	Silver, silk, atopic eczema and the CLOTHES trial â€“ reply to a letter. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e169.	2.4	0
70	Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 2019, 181, 459-473.	1.5	288
71	Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019. International Archives of Allergy and Immunology, 2019, 178, 207-218.	2.1	42
72	Perioral Dermatitis Successfully Treated with Topical Ivermectin. Annals of Dermatology, 2019, 31, S27.	0.9	6

#	Article	IF	Citations
73	Reply to a correspondence addressing the European guideline for treatment of atopic eczema, functional textiles and the CLOTHES trial. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e153-e154.	2.4	0
74	Human and computational models of atopic dermatitis: AÂreview and perspectives by an expert panel of the International Eczema Council. Journal of Allergy and Clinical Immunology, 2019, 143, 36-45.	2.9	58
75	Methotrexate in atopic eczema â€“ Reply to a letter. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e155-e156.	2.4	0
76	Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 577-587.	2.4	31
77	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2018, 178, e332-e341.	1.5	96
78	Consensusâ€based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 657-682.	2.4	727
79	Conjunctivitis occurring in atopic dermatitis patients treated with dupilumabâ€“clinical characteristics and treatment. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1778-1780.e1.	3.8	132
80	Unopposed IL-36 Activity Promotes ClonalÂCD4+ T-Cell Responses withÂIL-17AÂProduction in GeneralizedÂPustularÂPsoriasis. Journal of Investigative Dermatology, 2018, 138, 1338-1347.	0.7	64
81	Dupilumab for treatment of atopic dermatitis. Expert Review of Clinical Pharmacology, 2018, 11, 467-474.	3.1	135
82	Effects of a proteinâ€free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1-15.	2.4	32
83	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1059-1065.	2.4	150
84	Consensusâ€based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: partÂII. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 850-878.	2.4	519
85	Atopisches Ekzem. , 2018, , 549-568.		2
86	Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. Journal of Allergy and Clinical Immunology, 2018, 142, 1121-1130.e7.	2.9	195
87	Atopisches Ekzem. , 2018, , 1-21.		0
88	Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 845-853.e3.	2.9	87
89	Antiâ€“Interleukin-31 Receptor A Antibody for Atopic Dermatitis. New England Journal of Medicine, 2017, 376, 826-835.	27.0	470
90	Topical Therapy of AD: How to Reach Better Results. Current Dermatology Reports, 2017, 6, 137-143.	2.1	0

#	Article	IF	Citations
91	Pustular erythema multiforme major associated with atypical pneumonia. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e502-e503.	2.4	1
92	Atopic Dermatitis in Infants and Toddlers: a Diagnostic Challenge in Daily Practice. Current Dermatology Reports, 2017, 6, 230-240.	2.1	3
93	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 2017, 77, 623-633.	1.2	170
94	A practical approach to ichthyoses with systemic manifestations. Clinical Genetics, 2017, 91, 799-812.	2.0	17
95	Dapsone treatment for eosinophilic anular erythema. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e153-e154.	2.4	6
96	Atypical Forms of Hand, Foot, and Mouth Disease: A Prospective Study of 47 Italian Children. Pediatric Dermatology, 2016, 33, 429-437.	0.9	30
97	Photoallergic contact dermatitis due to treatment of pulmonary fibrosis with pirfenidone. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 370-371.	2.4	9
98	Key findings to expedite the diagnosis of hyperâ€IgE syndromes in infants and young children. Pediatric Allergy and Immunology, 2016, 27, 177-184.	2.6	39
99	ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 729-747.	2.4	329
100	New Perspectives in the Treatment of Atopic Dermatitis in the Pediatric Population. Pediatric, Allergy, Immunology, and Pulmonology, 2016, 29, 189-195.	0.8	0
101	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine, 2016, 375, 2335-2348.	27.0	1,467
102	Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2016, 138, 336-349.	2.9	465
103	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2016, 175, 69-79.	1.5	115
104	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. Journal of the American Academy of Dermatology, 2016, 75, 1038-1044.	1.2	35
105	Global Allergy Forum and 3rd Davos Declaration 2015. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 588-592.	5.7	47
106	Neurogenic inflammation and colliquative lymphadenitis with persistent orthopox virus<scp>DNA</scp>detection in a human case of cowpox virus infection transmitted by a domestic cat. British Journal of Dermatology, 2015, 173, 535-539.	1.5	11
107	Contact sensitization in patients with suspected cosmetic intolerance: results of the <scp>IVDK</scp> 2006â€“2011. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1071-1081.	2.4	44
108	Efficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study. Annals of Dermatology, 2014, 26, 462.	0.9	4

#	Article	IF	Citations
109	Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-Î³-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut, 2014, 63, 567-577.	12.1	267
110	Psychodermatological aspects of atopic dermatitis. British Journal of Dermatology, 2014, 170, 38-43.	1.5	96
111	Immunological and molecular targets of atopic dermatitis treatment. British Journal of Dermatology, 2014, 170, 7-11.	1.5	20
112	Beneficial IFN-Î± treatment of tumorous herpes simplex blepharoconjunctivitis in dedicator of cytokinesis 8 deficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 1456-1458.	2.9	19
113	Atopic dermatitis - all you can do from the outside. British Journal of Dermatology, 2014, 170, 19-24.	1.5	35
114	Atopic dermatitis, <scp>STAT</scp>3â€•and <scp>DOCK</scp>8â€hyperâ€IgE syndromes differ in IgEâ€based sensitization pattern. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 943-953.	5.7	86
115	Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, n/a-n/a.	5.7	1
116	Difficult to control atopic dermatitis. World Allergy Organization Journal, 2013, 6, 6.	3.5	29
117	Patch Testing for Noncontact Dermatitis: The Atopy Patch Test for Food and Inhalants. Current Allergy and Asthma Reports, 2013, 13, 539-544.	5.3	24
118	Management of Difficult-to-Treat Atopic Dermatitis. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 142-151.	3.8	143
119	Atopic dermatitis and skin allergies - update and outlook. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1509-1519.	5.7	29
120	Phacomatosis Pigmentokeratotica Is Caused by a Postzygotic HRAS Mutation in a Multipotent Progenitor Cell. Journal of Investigative Dermatology, 2013, 133, 1998-2003.	0.7	105
121	Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1507-1516.	3.3	6
122	Kinderdermatologie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 408-417.	0.0	0
123	Galenik â€“ Praktische Tipps und Beispiele. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 392-398.	0.0	0
124	Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1111-1117.	5.7	169
125	Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. European Journal of Medical Research, 2012, 17, 4.	2.2	20
126	Eczema Herpeticum. Chemical Immunology and Allergy, 2012, 96, 89-95.	1.7	32

#	Article	IF	Citations
127	Cutaneous Side Effects of New Antitumor Drugs. Deutsches Ärzteblatt International, 2012, 109, 133-40.	0.9	40
128	Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema. Annals of Dermatology, 2012, 24, 253.	0.9	114
129	Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers. JDDG - Journal of the German Society of Dermatology, 2012, 10, 559-562.	0.8	6
130	Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1045-1060.	2.4	495
131	Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1176-1193.	2.4	316
132	Skin diseases following a Christmas tree pattern. Clinics in Dermatology, 2011, 29, 189-194.	1.6	26
133	Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1114-1121.	5.7	201
134	Isotopic response, KÃ¶bner phenomenon and RenbÃ¶k phenomenon following herpes zoster. Journal of Dermatology, 2011, 38, 1058-1061.	1.2	22
135	Perioral dermatitis. JDDG - Journal of the German Society of Dermatology, 2011, 9, 422-427.	0.8	10
136	Periorale Dermatitis. JDDG - Journal of the German Society of Dermatology, 2011, 9, 422-428.	0.8	13
137	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. JDDG - Journal of the German Society of Dermatology, 2011, 9, 195-202.	0.8	28
138	Management kutaner Nebenwirkungen von EGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremiums fÃ¼r den primÃr behandelnden Arzt. JDDG - Journal of the German Society of Dermatology, 2011, 9, 195-203.	0.8	14
139	Innate Immunity in Atopic Dermatitis. Clinical Reviews in Allergy and Immunology, 2011, 41, 272-281.	6.5	76
140	Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Annals of Oncology, 2011, 22, 524-535.	1.2	104
141	Microbiological analysis of epidermal growth factor receptor inhibitor therapyâ€associated paronychia. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 958-960.	2.4	40
142	ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 317-328.	2.4	264
143	Treatment of atopic eczema with oral alitretinoin. British Journal of Dermatology, 2010, 162, 217-218.	1.5	47
144	Evolution of Conventional Therapy in Atopic Dermatitis. Immunology and Allergy Clinics of North America, 2010, 30, 351-368.	1.9	36

#	Article	IF	Citations
145	Diagnostic approach to the hyper-IgE syndromes: Immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. Journal of Allergy and Clinical Immunology, 2010, 126, 611-617.e1.	2.9	140
146	Leserâ€“Trelat sign in metastasized malignant melanoma. European Archives of Oto-Rhino-Laryngology, 2009, 266, 297-299.	1.6	16
147	Proactive therapy of atopic eczema â€“an evidenceâ€based concept with a behavioral background. JDDG - Journal of the German Society of Dermatology, 2009, 7, 117-121.	0.8	32
148	Proaktive Therapie des atopischen Ekzems â€“ ein evidenzbasiertes Therapiekonzept mit verhaltenstherapeutischem Hintergrund. JDDG - Journal of the German Society of Dermatology, 2009, 7, 117-121.	0.8	39
149	Proactive therapy of atopic dermatitis â€“ an emerging concept. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 276-278.	5.7	121
150	Therapie ungewÃ¶hnlicher Manifestationen und Komplikationen des atopischen Ekzems. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2009, , 143-147.	0.0	0
151	A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Experimental Dermatology, 2008, 17, 790-792.	2.9	44
152	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 742-750.	5.7	83
153	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 742-750.	5.7	211
154	Economic evaluation of maintenance treatment with tacrolimus 0Â·1% ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology, 2008, 159, 1322-1330.	1.5	35
155	A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. Journal of the American Academy of Dermatology, 2008, 59, 34-40.	1.2	45
156	Pollen Grains Induce a Rapid and Biphasic Eczematous Immune Response in Atopic Eczema Patients. International Archives of Allergy and Immunology, 2008, 145, 213-223.	2.1	39
157	Role of viruses. Series in Dermatological Treatment, 2008, , 69-76.	0.1	1
158	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 742-50.	5.7	26
159	Pimecrolimus cream (1%) efficacy in perioral dermatitis ? results of a randomized, double-blind, vehicle-controlled study in 40 patients. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 070525001847013-???.	2.4	34
160	Current Aspects of Innate and Adaptive Immunity in Atopic Dermatitis. Clinical Reviews in Allergy and Immunology, 2007, 33, 35-44.	6.5	54
161	Inflammatory Dendritic Epidermal Cells. , 2006, , 288-295.		1
162	Cathelicidin deficiency predisposes to eczema herpeticum. Journal of Allergy and Clinical Immunology, 2006, 117, 836-841.	2.9	252

#	Article	IF	Citations
163	Scoring of Skin Lesions with the Perioral Dermatitis Severity Index (PODSI). Acta Dermato-Venereologica, 2006, 86, 251-252.	1.3	16
164	Position paper on diagnosis and treatment of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 286-295.	2.4	122
165	The Role of Dendritic Cells in Cutaneous Lupus Erythematosus. , 2005, , 283-295.		3
166	Eczema herpeticatum. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2005, , 181-185.	0.0	0
167	The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 1318-1325.	5.7	244
168	Lessons from atopy patch testing in Atopic Dermatitis. Current Allergy and Asthma Reports, 2004, 4, 285-9.	5.3	61
169	Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2004, 114, 137-143.	2.9	61
170	Smallpox, vaccination and adverse reactions to smallpox vaccine. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 271-275.	2.3	66
171	Eczema molluscatum in tacrolimus treated atopic dermatitis. European Journal of Dermatology, 2004, 14, 73-4.	0.6	35
172	Viral infections in atopic dermatitis Pathogenic aspects and clinical management. Journal of Allergy and Clinical Immunology, 2003, 112, 667-674.	2.9	271
173	Clinical and immunologic reactivity to aeroallergens in â€œintrinsicâ€•atopic dermatitis patients. Journal of Allergy and Clinical Immunology, 2003, 111, 195-197.	2.9	59
174	Atopy patch test reactions show a rapid influx of inflammatory dendritic epidermal cells in patients with extrinsic atopic dermatitis and patients with intrinsic atopic dermatitis. Journal of Allergy and Clinical Immunology, 2003, 111, 869-874.	2.9	119
175	Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. Journal of the American Academy of Dermatology, 2003, 49, 198-205.	1.2	267
176	Phacomatosis Pigmentokeratotica (Happle) in a 23-Year-Old Man. Acta Dermato-Venereologica, 2002, 82, 55-57.	1.3	27
177	Long-lasting "Christmas Tree Rash" in an Adolescent: Isotopic Response of Indeterminate Cell Histiocytosis in Pityriasis Rosea?. Acta Dermato-Venereologica, 2002, 82, 288-291.	1.3	37
178	Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2002, 109, 547-555.	2.9	231
179	Expression and Function of the Mannose Receptor CD206 on Epidermal Dendritic Cells in Inflammatory Skin Diseases. Journal of Investigative Dermatology, 2002, 118, 327-334.	0.7	181
180	Enhanced Expression and Activity of Protein-tyrosine Kinases Establishes a Functional Signaling Pathway Only in FcÎµRIhigh Langerhans Cells from Atopic Individuals. Journal of Investigative Dermatology, 2002, 119, 804-811.	0.7	20

#	Article	IF	Citations
181	Plasmacytoid Dendritic Cells: A New Cutaneous Dendritic Cell Subset with Distinct Role in Inflammatory Skin Diseases. Journal of Investigative Dermatology, 2002, 119, 1096-1102.	0.7	384
182	The Intrinsic Type of Atopic Dermatitis Is Characterised by a Low Expression of the High-Affinity IgE Receptor FcÎµRI on Epidermal Dendritic Cells. , 2002, , 137-144.		0
183	Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Current Opinion in Investigational Drugs, 2002, 3, 708-12.	2.3	22
184	Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2001, 107, 519-525.	2.9	164
185	Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. Journal of the American Academy of Dermatology, 2001, 45, 736-743.	1.2	127
186	Mutations in CGI-58, the Gene Encoding a New Protein of the Esterase/Lipase/Thioesterase Subfamily, in Chanarin-Dorfman Syndrome. American Journal of Human Genetics, 2001, 69, 1002-1012.	6.2	435
187	Topical immunomodulatory agents and their targets in inflammatory skin diseases. Transplantation Proceedings, 2001, 33, 2212-2216.	0.6	10
188	In situ expression of the costimulatory molecules CD80 and CD86 on Langerhans cells and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis. Archives of Dermatological Research, 2001, 293, 448-454.	1.9	60
189	Essentielle diagnostische Verfahren in der Dermatologie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2001, , 499-505.	0.0	3
190	EcÉ›RI Expressing Dendritic Cells: The Missing Link in the Pathophysiology of Atopic Dermatitis ?. Journal of Dermatology, 2000, 27, 698-699.	1.2	7
191	Phenotyping of epidermal dendritic cells allows the differentiation between extrinsic and intrinsic forms of atopic dermatitis. British Journal of Dermatology, 2000, 143, 1193-1198.	1.5	76
192	Atopic dermatitis: pathogenetic mechanisms. Clinical and Experimental Dermatology, 2000, 25, 530-534.	1.3	79
193	Atopic dermatitis: from the genes to skin lesions. Allergy: European Journal of Allergy and Clinical Immunology, 2000, 55, 205-213.	5.7	129
194	Dorfman-Chanarin Syndrome in a Turkish Kindred: Conductor Diagnosis Requires Analysis of Multiple Eosinophils. Acta Dermato-Venereologica, 2000, 80, 39-43.	1.3	30
195	Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis. Archives of Dermatology, 2000, 136, 999.	1.4	368
196	Phenotyping of epidermal dendritic cells: Clinical applications of a flow cytometric micromethod. Cytometry, 1999, 37, 147-155.	1.8	93
197	Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry, 1999, 37, 147-55.	1.8	15
198	IL-10 inhibits ICAM-1 expression on human Langerhans cells but not on keratinocytes, dermal endothelial cells or fibroblasts. Archives of Dermatological Research, 1998, 290, 477-482.	1.9	22

#	Article	IF	Citations
199	Demonstration of the low-affinity IgE receptor FcÎµRII/CD23 in psoriatic epidermis: inflammatory dendritic epidermal cells (IDEC) but not Langerhans cells are the relevant CD1a-positive cell population. Archives of Dermatological Research, 1998, 290, 517-521.	1.9	16
200	Acne conglobata and Klinefelter's syndrome. British Journal of Dermatology, 1997, 136, 421-423.	1.5	2
201	Urticaria haemorrhagica profunda. British Journal of Dermatology, 1997, 136, 108-11.	1.5	1
202	Acne conglobata and Klinefelter's syndrome. British Journal of Dermatology, 1997, 136, 421-3.	1.5	0
203	Immunomorphological and Ultrastructural Characterization of Langerhans Cells and a Novel, Inflammatory Dendritic Epidermal Cell (IDEC) Population in Lesional Skin of Atopic Eczema. Journal of Investigative Dermatology, 1996, 106, 446-453.	0.7	364
204	Characterization of the protein tyrosine phosphatase CD45 on human epidermal Langerhans cells. European Journal of Immunology, 1995, 25, 317-321.	2.9	26
205	Multiple superficial basal cell carcinomas (basalomatosis) following cobalt irradiation. British Journal of Dermatology, 1995, 133, 644-646.	1.5	17
206	Langerhans cell phenotyping: a new tool for differential diagnosis of inflammatory skin diseases. Lancet, The, 1995, 346, 1626-1627.	13.7	84
207	Human keratinocytes release the endogenous beta-galactoside-binding soluble lectin immunoglobulin E (IgE-binding protein) which binds to Langerhans cells where it modulates their binding capacity for IgE glycoforms.. Journal of Experimental Medicine, 1993, 178, 777-785.	8.5	73
208	Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon) Tj ETQq0 0 0 rgBT /Overlock 10 T	8.5	473